Overview of cancer immunotherapy targeting the PD-1/PD-L1 pathway (IMAGE)
Caption
A simplified schematic illustrating how cancer cells evade immune attack by expressing PD-L1, which binds to PD-1 on T cells and suppresses their activity. The figure also shows how immune checkpoint inhibitors—anti-PD-1 or anti-PD-L1 antibodies—block this interaction, restoring T-cell activation and enabling immune-mediated tumor killing.
Credit
Kunihiro Tsuchida, Fujita Health University, Japan
Usage Restrictions
You are free to share and adapt the material. Attribution is required.
License
Original content